Journal
JOURNAL OF INFECTION AND CHEMOTHERAPY
Volume 23, Issue 9, Pages 658-660Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jiac.2017.02.004
Keywords
Chronic pulmonary aspergillosis; Nontuberculous mycobacteria; Mycobacterium avium complex; Itraconazole; Rifabutin
Categories
Funding
- Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [NRF-2015R1A2A1A01003959]
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI15C2778]
Ask authors/readers for more resources
Patients with coexisting chronic pulmonary aspergillosis and nontuberculous mycobacterial lung disease may undergo treatment with both the antifungal itraconazole and the antimycobacterial rifamycin. However, rifamycins interact with itraconazole. We examined the effects of a 150 mg dose of rifabutin on serum itraconazole levels and found significantly lower levels in 28 patients receiving itraconazole with rifabutin (median, 0.65 mu g/ml) compared with 65 patients receiving itraconazole alone (median 3.45 mu g/ml, P < 0.001). One-third of patients receiving itraconazole and rifabutin reached the therapeutic range of serum itraconazole concentration. Therapeutic drug monitoring is strongly recommended during concomitant use of rifabutin and itraconazole. (C) 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available